Celyad Oncology Investor Relations Material
Latest events
H1 2023
Celyad Oncology
H2 2024
2 Apr, 2025
H1 2024
13 Sep, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Celyad Oncology SA
Access all reports
Celyad Oncology SA is a Belgium-based clinical-stage biotechnology company focused on the development of cell therapy solutions for cancer. The company specializes in chimeric antigen receptor T-cell (CAR-T) therapies, leveraging proprietary technologies to develop allogeneic and autologous approaches for the treatment of solid and hematologic tumors. Celyad Oncology conducts research and clinical trials in collaboration with academic and industry partners. The company is headquartered in Mont-Saint-Guibert, Belgium, and its shares are listed on the Euronext Brussels and the NASDAQ.
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
CYAD
Country
🇧🇪 Belgium